Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

1(13%)

Results Posted

0%(0 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_1

25%

Ph phase_2

63%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(4)

Other(1)

Detailed Status

Withdrawn3

Completed2

Terminated1

unknown1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (28.6%)

Phase 25 (71.4%)

Trials by Status

completed225%

terminated113%

unknown113%

active_not_recruiting113%

withdrawn338%

Recent Activity

1 active trials

Showing 5 of 8

withdrawnphase_2

Clinical Trials (8)

Showing 8 of 8 trials

NCT03017547Phase 2

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

Withdrawn

NCT03875560Phase 2

IC14 in Adult Patients With Dengue Fever

Withdrawn

NCT03508453Phase 2

IC14 for Treatment of Amyotrophic Lateral Sclerosis

Withdrawn

NCT06275893Phase 1

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

Completed

NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting

NCT03487263Phase 1

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Completed

NCT04309604

IC14 for ALS Patients Expanded Access

Unknown

NCT00233207Phase 2

IC14 Antibodies to Treat Individuals With Acute Lung Injury

Terminated

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8